Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

15.63 -0.19 (-1.20%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

3 Cash-Producing Stocks on Our Watchlist

September 12, 2025

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

Via StockStory

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

September 11, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone...

Via StockStory

Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone ↗

September 10, 2025

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

Via Stocktwits

Why Hims & Hers Health (HIMS) Stock Is Trading Up Today

September 10, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market.

Via StockStory

Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone ↗

September 10, 2025

The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company.

Via Investor's Business Daily

Topics ETFs

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence ↗

September 10, 2025

Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.

Via Benzinga

Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow ↗

September 09, 2025

The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause.

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Why Hims & Hers Health (HIMS) Stock Is Up Today

September 04, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst...

Via StockStory

Topics ETFs Economy

4 Top Stocks to Buy in September ↗

September 04, 2025

Here are four stocks to buy now that could offer investors upside in both the short and long term.

Via The Motley Fool

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗

September 02, 2025

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire ↗

August 25, 2025

Hims & Hers, which boasts a $9.7 billion market cap, is up 170% over the past year, though it's pulled back nearly 25% this past month.

Via Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗

August 25, 2025

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

Via Benzinga

Topics ETFs

Healthcare Technology Stocks Q2 Highlights: Hims & Hers Health (NYSE:HIMS)

August 21, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology stocks, starting...

Via StockStory

Defiance Rolls Out Leveraged ETFs Targeting AMD, Supermicro, Palantir, Hims & Robinhood ↗

August 21, 2025

Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income.

Via Benzinga

Topics ETFs

Got $5,000? 3 Tech Stocks to Buy and Hold for the Long Term ↗

August 21, 2025

As the value of your investment portfolio rises over time, you will also be better equipped for retirement.

Via The Motley Fool

Topics Artificial Intelligence

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets ↗

August 21, 2025

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

Via MarketBeat

Why Hims & Hers Health (HIMS) Stock Is Falling Today

August 19, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from...

Via StockStory

Topics ETFs Economy Lawsuit

What's Going On With Hims & Hers Shares Today? ↗

August 19, 2025

Hims & Hers Health shares are trading lower Tuesday after GoodRx announces a collaboration with Novo Nordisk.

Via Benzinga

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4 ↗

August 18, 2025

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

Via MarketBeat

Topics Artificial Intelligence

Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here ↗

August 18, 2025

Motley Fool Money checks in on some stock market news.

Via The Motley Fool

Topics Economy

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 18, 2025

Via Benzinga

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets ↗

August 18, 2025

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Via Benzinga

CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio? ↗

August 17, 2025

Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC probe may be the reasons.

Via Benzinga

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces ↗

August 15, 2025

Via Benzinga

1 Stock Under $50 with Solid Fundamentals and 2 We Ignore

August 15, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

Headline News about Hims & Hers Health, Inc. Class A Common Stock

Starting at $3.75/week.

Subscribe Today